“The frontier of innovation for the life science industry is defined by those who can bring sense to the overwhelming amount of data points generated every day. I am impressed by BenchSci’s ability and vision to do exactly that as it will not only improve research efficiencies but also bring the scientific community novel insights to complex biologic systems.”
Philip Larsen is the Senior Vice President and Global Head of Research at Bayer Pharmaceuticals. He joined Bayer in July 2019, before which he was Chief Scientific Officer at Grünenthal. Before that, he served as Chief Scientific Officer, German Hub at Sanofi. Larsen has 27 years of pharmaceutical and biotechnology industry experience focusing on diabetes and obesity, with 20 years of leading research divisions. After a few years of work at NovoNordisk and Zealand Pharma, he cofounded the Danish biotechnology company Rheoscience in 2001. In 2008, he took up a position as Chief Scientific Officer for Diabetes Research at Eli Lilly, Indianapolis, USA, before returning to Europe as Vice President for Early Clinical Development in CVM at AstraZeneca. He holds an M.D. and a Ph.D. in neuroendocrinology, both from the University of Copenhagen.